행사 소개
What To Expect At The World TPD & Induced Proximity Summit South Korea
South Korea has rapidly emerged as a global hub for targeted protein degradation (TPD), driven by strong government investment, a mature biopharma manufacturing ecosystem, and increasing R&D activity from both local pioneers and international pharma. With world-leading capabilities in biologics production, a growing number of innovative biotech startups, and expanding industry collaboration, the Korean TPD landscape is scaling quickly from discovery through to clinical development, making the region a key growth market for next-generation protein degradation technologies.
The inaugural World TPD & Induced Proximity Summit South Korea is an exclusive opportunity to connect with global pharma, including Astellas and Amgen, leading biotechs such as Ubix Therapeutics and Degron Therapeutics, and local leaders like Tanabe Pharma, FIMECS, and more to develop best-in-class TPD therapeutics. The program has been designed to help attendees integrate new proteomics and AI technologies into their workflow, optimize their strategy for clinical transition, and catch the latest data from discovery to clinic across PROTACs, molecular glues, and degrader antibody conjugates (DACs).
Whether you’re taking candidates to clinic, accelerating molecular glue discovery, or seeking global partnerships, join 80+ Directors, Heads, and Scientists to gain a holistic perspective and stay ahead in Asia’s fast-growing TPD market and deliver more targeted, efficacious, and safer therapies for patients.
This event is part of the World Targeted Therapeutics Summit South Korea, so attendees will also have access to sessions for the 5th World ADC South Korea Summit and the inaugural World Bispecifics & T-Cell Engager Summit South Korea.
Unmissable Event Highlights
참가자 혜택
Fast-track clinical candidates by learning how to navigate the transition from discovery to clinic with leaders who have successfully advanced degraders into human trials, including Astellas and BeOne Medicines
De-risk TPD candidates across discovery, PK/PD, and clinical development through real-world case studies showcasing robust datasets from first-in-class PROTACs and DACs from Orum Therapeutics, Ubix Therapeutics, AUTOTAC Bio, and more
Accelerate TPD workflows by integrating the latest platform and AI technologies with pioneering developers, including AIGEN Sciences and SK Life Sciences
Unlock historically undruggable targets at the frontier of induced proximity innovation, from ubiquitin-independent proteasome engagement to endocytosis independent degradation of transmembrane proteins led by academic experts from Fudan University and Seoul National University
Position Korean TPD candidates for global impact by learning how to validate pipelines, structure pharma-biotech collaborations, and scale emerging companies with perspectives from Amgen, Yuhan Corporation, Pin Therapeutics, and more
Download the Official Agenda to Explore:
공식 아젠다를 다운로드하여 다음 내용을 확인하세요:
- Your One-Stop Forum to De-Risk & Develop Best-in-Class TPD Therapeutics
- Insights from 20+ Korean-Based and International Speakers
- Unrivalled Networking Opportunities with Professionals Working on TPD & Induced Proximity, ADCs, Bispecifics & T-Cell Engagers
Attending Companies Include
참석 기업 목록
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.